Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05253339
Other study ID # 2022-0180
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 4, 2022
Est. completion date April 30, 2025

Study information

Verified date March 2024
Source Asan Medical Center
Contact Byung-Moon Choi, Ph.D.
Phone 82230101704
Email byungmoonchoi7@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Preoperative antimicrobial prophylaxis is a key element for the prevention of surgical site infection, the most common type of nosocomial infection in surgical patients. Prophylactic antibiotics are selected depending on the type of surgery, and first- or second-generation cephalosporins have been mainly used. Cefoxitin, a second-generation cephalosporin with anaerobic activity, has been used in various clinical settings as a prophylactic antibiotic for colorectal surgery. Cefoxitin is generally dissolved in normal saline and intravenously administered for a short time of 5-10 minutes before skin incision. However, there are several drawbacks to the current dosing strategy. First, the dose of cefazolin is determined by a "rule of thumb", and there is controversy over whether 1 g or 2 g is appropriate, with the opinion that 2 g being more appropriate prevailing. Second, the standard administration method unnecessarily induces a concentration higher than the concentration required to prevent surgical site infection. Third, significant covariates that can affect the maintenance of MIC during surgery are not considered. The target-concentration controlled infusion (TCI) method can be a viable alternative administration method for antibiotics. The TCI method enables individual customized administration according to the covariates (i.e., weight, creatinine clearance) included in the pharmacokinetic parameters; also, although with some variability, the drug can be administered while maintaining the target concentration. The aim of this study was to evaluate the effectiveness of administering cefoxitin in patients undergoing colorectal surgery with a syringe pump equipped with a target concentration control injection function


Description:

Parenteral antimicrobial prophylaxis before abdominal surgery for preventing surgical site infection (SSI) is a well-established clinical practice. Prophylactic antibiotics are selected depending on the type of surgery, and first- or second-generation cephalosporins have been mainly used. These antibiotics are generally dissolved in normal saline and intravenously administered for a short time of 5-10 min before skin incision. However, the conventional administration strategy has several problems. First, the dose of antibiotics does not take into account the patients' physical characteristics such as body weight, age, and renal function. Considering that the dosages of practically all drugs used in clinical fields are determined based on body weight, it may be necessary to improve the dosing strategy to reflect the patient's physical characteristics based on the effectiveness and safety of the antibiotic. Second, the plasma concentration of cephalosporin becomes excessively high at the end of the administration, which is more pronounced in patients with low body weight. The minimal inhibitory concentrations (MIC) for each antibiotic are well-characterized; however, a pilot simulation study showed that at the end of the administration, the plasma concentration of cefazolin was 20 times higher than its MIC. It is difficult to exclude the possibility that concentrations higher than necessary may cause harm to patients. Third, the bactericidal activity of an antibiotic is apparent when its free plasma concentration is maintained above the MIC. Using the conventional administration method, there is a period during the entire surgical period in which the concentration decreases below the MIC unless redosing is performed. Taken together, it is necessary to develop a method for administering a prophylactic antibiotic to overcome these problems. The target-controlled infusion (TCI) is a method of administering a drug while maintaining a target concentration and has been used for more than 20 years for administering hypnotic agents and opioids during general anesthesia. Because the infusion rate is continuously recalculated by an infusion algorithm mounted on the TCI infusion pump to maintain the target concentration, the infusion rate is not fixed and changes over time. The patient's specific characteristics such as body weight and creatinine clearance can be included in the pharmacokinetic parameters so that even when administered for the same duration and the same target concentration, the actual dosage varies for each patient and allows for personalized administration. Thus, the population pharmacokinetic parameters of a drug are required to administer the drug by the TCI method. The risk of SSI varies depending on the type of surgery, and colorectal surgery is regarded as having a high risk of SSI because of the possibility of wound contamination from bowel contents. Accordingly, the incidence of SSI has been reported to be 4-10% in colon surgery and 3-27% in rectal surgery. In the case of colorectal surgery, the optimal prophylactic antibiotic has not been unified into one agent. Cefoxitin, a second-generation cephalosporin with anaerobic activity, has been used in various clinical settings as a prophylactic antibiotic for colorectal surgery. The aim of this study was to evaluate the effectiveness of administering cefoxitin in patients undergoing colorectal surgery with a syringe pump equipped with a target concentration control injection function


Recruitment information / eligibility

Status Recruiting
Enrollment 2494
Est. completion date April 30, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - over 20 years old - Patients who are scheduled to undergo colon or rectal surgery - Patients scheduled to receive cefoxitin as a prophylactic antibiotic Exclusion Criteria: - Known allergies, hypersensitivity, or intolerance to cefoxitin - Patients with a history of receiving cefoxitin within 3 days of the scheduled surgery time - Patients receiving therapeutic antibiotics - eGFR < 30 ml/min/1.73m2

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
target-controlled infusion (one of the administration methods)
a method of administering cefoxitin while maintaining a constant target concentration.
Standard administration method
Standard method of administering cefoxitin in the current clinical setting

Locations

Country Name City State
Korea, Republic of Asan Medical Center Seoul Songpa-Gu,

Sponsors (2)

Lead Sponsor Collaborator
Asan Medical Center Seoul Business Agency

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other The incidence of acute kidney injury An increase in serum creatinine by = 0.3 mg/dl within 48 h or an increase in serum creatinine to = 1.5 times baseline within the previous 7 days or urine volume = 0.5 ml/kg/h for 6 h Within 7 days after the operation
Primary The incidence of surgical site infections Surgical site infection (SSI) is an infection that occurs after surgery in the part of the body where the surgery took place. Superficial incisional SSI occurs just in the area of the skin where the incision was made. Deep incisional SSI occurs beneath the incision area in muscle and the tissues surrounding the muscles. Organ-space SSI includes infections involving any part of the anatomy that was opened or manipulated during an operation Within 30 days after the operation
Secondary Total dose of cefoxitin Total amount of cefoxitin administered as prophylactic antibiotics. Redosing is performed every two hours after the first dose. on the day of surgery
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1
Completed NCT00984009 - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1